Kuano
Kuano offers a computational drug design platform that helps researchers identify safer, more efficient drug candidates faster. It combines quantum mapping, AI and machine-learning-driven simulations through its proprietary Quantum Lens technology to model binding, reactivity and subtle electronic features that conventional methods miss. The platform integrates quantum chemistry, in silico simulation, and medicinal chemistry workflows to support design of enzyme inhibitors, allosteric binders, covalent ligands and other modalities. Kuano operates as a B2B platform working with pharmaceutical and biotech organizations on target-driven discovery and inhibitor design.
Kuano
Kuano offers a computational drug design platform that helps researchers identify safer, more efficient drug candidates faster. It combines quantum mapping, AI and machine-learning-driven simulations through its proprietary Quantum Lens technology to model binding, reactivity and subtle electronic features that conventional methods miss. The platform integrates quantum chemistry, in silico simulation, and medicinal chemistry workflows to support design of enzyme inhibitors, allosteric binders, covalent ligands and other modalities. Kuano operates as a B2B platform working with pharmaceutical and biotech organizations on target-driven discovery and inhibitor design.
TL;DR
What: Quantum simulation + AI platform for small‑molecule drug design
Founded: 2020
Location: Cambridge / London, UK
Stage: Seed (latest round 2023-09-12)
Total funding: 3,627,438 USD
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Drug discovery and small‑molecule design, including challenging enzyme targets and advanced binding/reactivity modelling.
Founded
2020
Industry
Biotechnology
Tech Stack
Funding Track Record
Pre‑seed round announced with o2h human health EIS Fund leading a consortium of investors.
£1,000,000
Seed round reported as £1m with participation from a syndicate of angels.
£1,800,000
Seed round that brought total investment raised to date to approximately £2.8M.
Investor Signal
“Investor syndicate includes Mercia Ventures, ACF Investors, o2h Ventures, Ascension Ventures, Meltwind Advisory and other angel investors”